Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of
AVEO Pharmaceuticals, Inc.
SAN DIEGO -- May 2, 2013
Shareholder rights law firm Johnson & Weaver, LLP has commenced an
investigation into whether certain officers and directors of AVEO
Pharmaceuticals, Inc (NASDAQ: AVEO) violated state or federal laws when
recently communicating their outlook for AVEO’s anticipated FDA approval of
According to Johnson & Weaver, LLP, shares of AVEO declined more than 58% in
early trading on Thursday, May 2, 2013, after Members of the Food and Drug
Administration advisory panel rejected approval for AVEO’s drug tivozanib by a
vote of 13-1. The FDA panel specifically criticized AVEO for relying on a
single-final phase clinical trial and stated that the company should conduct
another study to better assess the benefits.
Johnson & Weaver’s investigation is ongoing, with particular focus on whether
AVEO management misrepresented tivozanib’s clinical trial results or prospects
for FDA approval. Jim Baker, Lead Analyst for Johnson & Weaver, stated that,
"It is quite peculiar that AVEO was banking on this limited trial information
to boast about the potential FDA approval.”
If you have information that could assist in this investigation or if you are
an AVEO shareholder and are interested in learning more about the
investigation or your legal rights and remedies, please contact Jim Baker
(email@example.com)by email or by phone at 619-230-0063.
Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law
firm. The firm represents individual and institutional investors in
shareholder derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
Johnson & Weaver, LLP
619-230-0063, Ext. 118
Press spacebar to pause and continue. Press esc to stop.